Evidence map›Paper›PMID 42488382›Full record

ArticleFrontiers in neurology

Most common, burdensome, and worrisome symptoms experienced by people living with early Parkinson's disease in Germany and the United States-Results from a cross-sectional survey.

Simon Messner, Àngels Costa, Todd Carmody, Rebekah Park, Byron Jones, Elisabeth Lucassen, Amelia Hursey

Abstract read
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simon MessnerNovartis Pharma AG, Basel, Switzerland.
Àngels CostaNovartis Pharma AG, Basel, Switzerland.
Todd CarmodyGemic, New York, NY, United States.
Rebekah ParkGemic, New York, NY, United States.
Byron JonesNovartis Pharma AG, Basel, Switzerland.
Elisabeth LucassenNovartis Pharma AG, Basel, Switzerland.
Amelia HurseyParkinson's Europe, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The majority of research on the patient experience of Parkinson's disease (PD) has focused on the frequency and burden of late-stage symptoms, with less emphasis on understanding symptoms in the earlier phases of the condition. Objective: This descriptive, cross-sectional study aimed to identify the most common, burdensome, and worrisome symptoms of early-stage PD (ePD). Methods: An online, self-administered survey was completed by people with ePD (within 5 years of diagnosis) living in the United States and Germany. Descriptive statistics were used to report respondents' characteristics and responses to the survey questions. Results: Out of a total of 150 survey participants, 106 were diagnosed with ePD for 0-3 years, while 44 participants were diagnosed for 4-5 years. All respondents reported experiencing tremor, which, together with mobility issues and pain, were most frequently reported as the most burdensome symptoms in both groups. Bradykinesia, mobility issues, memory loss/time lapse, cognitive impairment, and urinary and gastrointestinal problems were reported with a frequency of at least 30% higher in the 4-5-year group. Conclusion: In the surveyed population, the reported frequency of symptoms such as tremor, mobility issues, and pain was higher among those who were 4-5 years post-diagnosis, and these symptoms were reported as the most burdensome. The frequency and impact of motor and non-motor symptoms should be evaluated in future interventional clinical trials involving people living with ePD.

Indexed as

early-stagenon-motor symptomParkinson’s diseasepatient-reported symptomstremor-dominant

Identifiers

PMID42488382
PMCPMC13388077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.